Evidence map›Paper›PMID 32610044›Full record

ArticleStructure (London, England : 1993)2020

Computationally Designed Cyclic Peptides Derived from an Antibody Loop Increase Breadth of Binding for Influenza Variants.

Alexander M Sevy, Iuliia M Gilchuk, Benjamin P Brown, Nina G Bozhanova, Rachel Nargi, Mattie Jensen, Jens Meiler, James E Crowe

Open access · bronzeAbstract read
In one paragraph

Article in Structure (London, England : 1993), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.1field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Structural Classification of CDR-H3 in Single-Domain VMethods in molecular biology (Clifton, N.J.) · 2023
    Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Alexander M SevyChemical & Physical Biology Program, Vanderbilt University, Nashville, TN 37235, USA; Center for Structural Biology, Vanderbilt University, Nashville, TN 37235, USA; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Iuliia M GilchukVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Benjamin P BrownChemical & Physical Biology Program, Vanderbilt University, Nashville, TN 37235, USA; Center for Structural Biology, Vanderbilt University, Nashville, TN 37235, USA.
Nina G BozhanovaCenter for Structural Biology, Vanderbilt University, Nashville, TN 37235, USA; Department of Chemistry, Vanderbilt University, Nashville, TN 37235, USA.
Rachel NargiVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Mattie JensenVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Jens MeilerChemical & Physical Biology Program, Vanderbilt University, Nashville, TN 37235, USA; Center for Structural Biology, Vanderbilt University, Nashville, TN 37235, USA; Department of Chemistry, Vanderbilt University, Nashville, TN 37235, USA. Electronic address: jens.meiler@vanderbilt.edu.
James E CroweChemical & Physical Biology Program, Vanderbilt University, Nashville, TN 37235, USA; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA. Electronic address: james.crowe@vanderbilt.edu.
Vanderbilt University · USVanderbilt University Medical Center · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007347 · NIGMS · VANDERBILT UNIVERSITY · PI WILLIAMS, CHRISTOPHER S. · 1985 to 2023
$26.3M
Structure based design of antibodies and vaccinesU19AI117905 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CROWE, JAMES E · 2015 to 2019
$12.0M
Medical Scientist Training ProgramT32GM152284 · NIGMS · VANDERBILT UNIVERSITY · PI Christopher S. Williams · 2024 to 2026
$4.8M
Epitope-Based Design and Modified RNA Platform for Bivalent Marburgvirus VaccineR01AI141661 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI BUKREYEV, ALEXANDER, CROWE, JAMES E · 2019 to 2023
$3.9M
High-Performance Computer Cluster for Biomedical ResearchS10OD023680 · OD · VANDERBILT UNIVERSITY · PI MEILER, JENS · 2017 to 2017
$587k
Targeting receptor tyrosine kinases with novel methods in computer-aided drug discovery for the treatment of fibrotic renal diseaseF30DK118774 · NIDDK · VANDERBILT UNIVERSITY · PI BROWN, BENJAMIN PATRICK · 2018 to 2021
$162k
NIAID NIH HHS HHSN272201400024CNIAID NIH HHS R01 AI141661NIAID NIH HHS U19 AI117905NIDDK NIH HHS F30 DK118774NIGMS NIH HHS T32 GM007347NIGMS NIH HHS T32 GM152284NIH HHS S10 OD023680
6 · The paper itself

Abstract

The influenza hemagglutinin (HA) glycoprotein is the target of many broadly neutralizing antibodies. However, influenza viruses can rapidly escape antibody recognition by mutation of hypervariable regions of HA that overlap with the binding epitope. We hypothesized that by designing peptides to mimic antibody loops, we could enhance breadth of binding to HA antigenic variants by reducing contact with hypervariable residues on HA that mediate escape. We designed cyclic peptides that mimic the heavy-chain complementarity-determining region 3 (CDRH3) of anti-influenza broadly neutralizing antibody C05 and show that these peptides bound to HA molecules with <100 nM affinity, comparable with that of the full-length parental C05 IgG. In addition, these peptides exhibited increased breadth of recognition to influenza H4 and H7 subtypes by eliminating clashes between the hypervariable antigenic regions and the antibody CDRH1 loop. This approach can be used to generate antibody-derived peptides against a wide variety of targets.

Indexed as

AnimalsAntibodies, MonoclonalAntibodies, NeutralizingBinding Sites, AntibodyComplementarity Determining RegionsDogsDrug DesignEpitopesHemagglutinin Glycoproteins, Influenza VirusInfluenza A Virus, H1N1 SubtypeMadin Darby Canine Kidney CellsMolecular Dynamics SimulationPeptides, CyclicProof of Concept StudyProtein ConformationProtein EngineeringAntibodies, MonoclonalAntibodies, NeutralizingComplementarity Determining RegionsEpitopesHemagglutinin Glycoproteins, Influenza VirusPeptides, Cyclicimmunologyinfluenza inhibitorspeptide designprotein design

Identifiers

PMID32610044
PMCPMC7544621
OpenAlexW3039824690

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.